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Summary
Recent insights into the cell biology of the epidermis and its appendages are
transforming our understanding of the pathogenesis of basal cell carcinoma
(BCC). The significant progress that has been made warrants a comprehensive
review of the molecular and cellular pathology of BCC. The items addressed
include environmental and genetic risk factors, the biology of the putative pre-
cursor cell(s), and the contribution of aberrations in processes such as apoptosis,
cell proliferation, differentiation and signalling to carcinogenesis. Furthermore,
established and novel treatment modalities are discussed with particular attention
to future biological approaches.
Basal cell carcinoma (BCC), also called basalioma, basal cell
epithelioma, rodent ulcer and Jacobs’ ulcer, was first described
in 18241 and is the most common cancer among Caucasians.2
BCC accounts for approximately 75% of all skin cancers. Mor-
tality rates are low,3 but BCC may occasionally grow aggres-
sively causing extensive tissue destruction.4 Its frequency of
metastasis is very low (<0Æ1%).5 Metastasis to lymph nodes,
lung, bone and liver has been described.6,7
BCCs are commonly subdivided according to their differ-
ences in histological appearance.8,9 The major histological pat-
terns are nodular, micronodular, superficial and morpheaform
BCC. The nodular type is characterized by a rounded mass of
neoplastic cells with well-defined peripheral contours and per-
ipheral palisading. The superficial type is defined by one or
more tumour foci that extend from the epidermis into the
papillary dermis. Peripheral palisading occurs and the periph-
eral contours are smooth. The micronodular subtype grows as
small nodules, hence the name. Peripheral palisading is usually
present. The morpheaform subtype consists of tumour islands
of varying size with an irregular outline and spiky configur-
ation. Peripheral palisading is poorly developed. Mixed types
of these histological patterns may occur, with the nodular–
micronodular combination being the most common.10 Fur-
thermore, central nodular and peripheral morphea-like growth
can occur. Finally, a so-called adenoid pattern is seen in 1–7%
of the tumours and is mainly associated with the nodular
growth type.11 Nodular (~60%) and superficial (~25%) BCCs
are often considered as non-aggressive subtypes, whereas mor-
pheaform (~2%) and micronodular (~15%) BCCs are often
referred to as aggressive subtypes, associated with a higher
risk of local recurrence.12
Risk factors
The risk for development of BCC is associated with environ-
mental factors as well as several patient-dependent factors.
Environmental risk factors
Sun exposure
BCCs generally occur on sun-exposed areas of the body13 and
high-risk patients are often fair-skinned with a history of
burning, not tanning, when exposed to sunlight.14 Male sex,
older age and number of previous second-degree sunburns are
also factors indicating a higher risk for development of BCC.15
Corona et al. 16 showed in 2001 that there is a significant
association between BCC development and recreational sun
exposure during childhood and adolescence, as well as a
strong relationship with family history of skin cancer. Patients
with a BCC located on the trunk are at increased risk of devel-
oping multiple BCCs, and these tumours develop at a faster
rate than BCCs located elsewhere on the body.17 Grossman
and Leffell18 showed that there is a correlation between ultra-
violet (UV)-B exposure and the development of skin cancer.
However, the significant number of BCCs arising on non-sun-
exposed areas of the body suggests that other risk factors may
play a role in the development of BCC.19
Chemical carcinogens and radiation
Diepgen and Mahler20 found that chemical carcinogens such
as arsenic, coal tar products and psoralens as well as ionizing
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radiation increase the risk of non-melanoma skin cancer,
mainly squamous cell carcinoma (SCC). With respect to the
relationship between smoking and skin cancer development,
de Hertog et al.21 showed an association with SCC but not
BCC, while Boyd et al.22 recently proved that an association
exists between smoking and BCC in young women. Further-
more, exposure to fibreglass dust and dry-cleaning agents has
also been reported to enhance the risk for BCC development.19
However, this is one report and the findings in it have yet to
be confirmed. We find it difficult to think of a pathogenic
mechanism to explain the carcinogenic potential of fibreglass
on skin.
Exposure to psoralens combined with UVA-treatment
(PUVA) in psoriasis patients has been reported to result in an
increased risk for BCC and SCC.23–25 However, later studies
failed to substantiate the increased risk of BCC and it is
currently doubted whether BCC can really result from PUVA
therapy.26,27 Melanoma risk is also increased by PUVA.27 Prior
non-diagnostic X-ray treatment for skin conditions also
enhanced the risk for BCC.19 In general, it seems that DNA-
damaging agents predispose more to SCC than they do to
BCC. This observation is consistent with the spectrum of
malignancies observed in congenital disorders of DNA repair
(discussed below).
Viral carcinogenesis
Several authors demonstrated an association between infection
with the oncogenic types of human papillomavirus (HPV) and
development of BCC,28–30 while Harwood and Proby31
showed that HPV could abrogate UV-induced apoptosis. Fur-
thermore, HPV DNA was detected in BCC patients by Barr
et al.28 and Weinstock et al.30 suggesting that HPV infection
may play a role in developing BCC. To date, a causal connec-
tion has not been established and it seems doubtful that one
will be found.
Hereditary predisposition
Detoxifying proteins
Proteins that mediate detoxification processes, including indi-
vidual responses to UV irradiation by protecting from oxida-
tive stress, are likely to be involved in susceptibility for BCC.32
For example, glutathione S-transferase (GST) enzymes are part
of the cells’ defence mechanism against harmful chemicals
produced endogenously and in the environment.33 UV irradi-
ation causes oxidative stress in the skin, which leads to lipid
peroxidation and DNA hydroperoxide formation.34 GST is
responsible for the disposal of these potential mutagens.35
Cytosolic GST activity in mammalian tissues is due to the pres-
ence of multiple GST isozymes, which can be assigned to five
classes, e.g. a, h, l, p and r.36 In human skin, GST activity is
found predominantly in sebaceous glands and in the outer
root sheath (ORS) of hair follicles, the p-class of GST being
the predominant isozyme.37 GST-p has been suggested to be
an oncofetal protein that is re-expressed during carcinogene-
sis.38 A significant increase in skin tumorigenesis is observed
in mice lacking p-class GST.39 This finding seems to contradict
the oncogene hypothesis, but in humans, GST-p is expressed
in malignant melanomas,40 whereas BCCs show only a weak
expression of the protein.41 Obviously, this apparent contra-
diction needs to be addressed if we are to understand the role
of GST-p in human tumorigenesis, if any. Conditional (skin-
specific) GST-p knockout mice could be used as a model
system. Several polymorphisms in GST family members
exist36,42 and have been associated with impaired detoxifica-
tion, thus influencing the risk for several cancers, including
non-melanoma skin cancer.43,44 A GSTT1 null genotype is asso-
ciated with high UV sensitivity,45 and a GSTM1 null genotype
also predisposes for BCC, probably due to its role in defence
against UV-induced oxidative stress.32,46 Polymorphism of
GSTM3 was also shown to increase risk for BCC.47 Another
genetic factor involved in detoxification of photosensitizing
agents, and thus involved in BCC carcinogenesis, is poly-
morphism of CYP2D6 (the gene encoding cytochrome P450),
which is correlated with an increased number of BCCs.46
Furthermore, some allelic variants of CYP2D6 are associated
with a multiple presentation phenotype of BCC48,49 and these
patients are also at higher a priori risk for developing BCC.50
DNA repair
In 1973, Milstone and Helwig51 noted that patients with xero-
derma pigmentosum (XP), a group of rare autosomal recessive
disorders characterized by severe photosensitivity due to var-
ious defects in DNA repair, are prone to developing cutaneous
cancers, mostly SCC but also BCC and malignant melan-
oma.52–54 There are several variants of the disease, all caused
by a different genetic defect in nucleotide excision repair, glo-
bal genome repair, transcription-coupled repair or combina-
tions thereof. Some of the genes involved are essential
components of the TFIIH transcription complex; their absence
is associated not only with UV sensitivity but also with some-
times severe neurological defects and growth retardation
(as in de Sanctis–Cacchione syndrome).55 Interestingly, at least
two types of XP are caused by defects in DNA helicases that
are involved in nucleotide excision repair and in transcription.
Werner and Bloom syndromes are hereditary skin cancer dis-
orders that are associated with helicase defects but, curiously,
not with the development of BCCs.56,57 Rothmund–Thomsen
syndrome, which in some cases is caused by defects in a DNA
helicase,58 does seem to predispose to BCC.59 The reason for
this difference is poorly understood. The expression patterns
of helicases may play a role but it is not clear why helicases
should be tissue-specific. Chromosomal breakage disorders
such as ataxia teleangiectasia and Nijmegen breakage
syndrome do not predispose to BCC. Neither does Li–Fraumeni
syndrome, which can be caused by germline mutations in the
p53 gene,60 nor dyskeratosis congenita, a disorder associated
with failure to maintain telomeres.61,62 Why these forms of
genomic instability do not seem to be causally related to BCC
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is uncertain. It may reflect a very basic biological difference
between BCC and other malignancies. Whereas most tumours
sooner or later show chromosomal instabilities,63 BCC does
not seem to do so.
Embryonic signalling pathways – Hedgehog, Wingless,
Ectodysplasin and NF-kB
Patients with the nevoid BCC syndrome (NBCCS) or Gorlin
syndrome,64 show a rapid development of numerous BCCs
at a young age. Whereas XP is an autosomal recessive
disorder, NBCCS is an autosomal dominant disorder.65 A
human homologue to the Drosophila segment polarity gene
patched, PTCH1 (there is also a PTCH2 of as yet unknown
importance) is mutated in NBCCS patients, suggesting a
contribution to the tumorigenesis.66,67 As NBCCS patients
normally inherit one mutated copy of the PTCH gene,
tumours are likely to arise after inactivation of the remain-
ing allele.68 Haploinsufficiency of the PTCH1 gene is prob-
ably responsible for the dysmorphisms. XP patients and
sporadic BCCs may also show mutations in the PTCH
gene.69–71 The PTCH1 gene product is part of a receptor for
a protein called Sonic Hedgehog, which is involved in
embryonic development.72 Sonic hedgehog (SHH) is
expressed in the Hensen node, the floorplate of the neural
tube, the early gut endoderm, the posterior limb buds and
throughout the notochord, and encodes a signal responsible
for patterning the early embryo.73–75 When SHH binds to
PTCH, it releases smoothened (SMOH), a transmembrane
signalling protein, from inhibition by PTCH (Fig. 1).76 It is
now believed that PTCH modulates SMOH in an indirect
manner,77 although it is not known how. There is some
evidence that PCTH may influence the localization or intra-
membrane conformation of SMOH.78 SMOH in turn signals
to GSK3b, which phosphorylates GLI3 (a human ortholog
of the Drosophila gene cubitus interruptus). It is assumed that the
human orthologues of Costal2, Fused and Suppressor of Fused
(Su(Fu)) then form a tetramer as they do in Drosophila but so
far, only Su(Fu) has been demonstrated in humans.79 The
complex then translocates, possibly via the microtubule-
binding activity of Costal2, which has kinesin activity, to the
nucleus where it can regulate activity of target genes such
as WNT genes, BMP and PTCH1 itself (Fig. 1 and reviewed
in80). WNT signals are transduced via the APC ⁄Axin ⁄DSH
complex which inhibits GSK3b activity; as a result, b-catenin
is not degraded and complexes with TCF ⁄Lef1 into a tran-
scription complex which is active in early hair follicle
growth and in the initiation of anagen.81 b-catenin, in turn,
can influence the NFkB pathway (see below). Activating
mutations of b-catenin give rise to pilomatricoma, another
hair follicle tumour, clearly showing the importance of
b-catenin-mediated signalling for hair follicle growth.82,83
Such mutations have not yet been found in BCC, and it
would be of interest to look for such alterations in sporadic
BCCs. Thus, a staggeringly complex regulatory network
emerges. It is of interest to note that it is essential for hair
follicle morphogenesis, suggesting that the development of
BCC in the context of PTCH1 mutations may represent
uncontrolled hair follicle morphogenesis.
The high frequency of mutations in SMOH and PTCH1 in
BCCs, resulting in continuous activation of target genes, indi-
cates that a disturbed HEDGEHOG pathway, resulting in exces-
sive signalling, may be an important carcinogenic route.84 UV
irradiation enhances BCC development in PTCH1 mutant
mice.85 Of the sporadic BCCs 20% show SMOOTHENED
mutations86 and 30–40% patched mutations.70 In XP patients,
the majority (~80%) of PTCH1 mutations are UV-induced,87
as expected more frequently than in sporadic BCCs,70 where
UV-signature mutations are seen in less than 50%.88 PTCH2,
Fig 1. A simplified representation of the Sonic Hedgehog signalling
network and its cross-talk with the Wnt signalling pathway. See the
text for an explanation. GSK3b, glycogen synthetase kinase 3b; FU,
Fused; SU(FU), suppressor of fused; GLI, cubitus interruptus
homologues; BMP, bone morphogenetic proteins; WNT, secreted
Wingless signalling protein; CBP, CREB binding protein; TCF ⁄LEF,
transcription control factor ⁄ lymphoid enhancer factor; DSH,
dishevelled family protein; APC, adenomatous polyposis coli protein.
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which is 57% identical to PTCH1, probably also serves as a
receptor for hedgehog and related factors.89 Mutations occur
in sporadic BCC,90 and it has been shown that when PTCH1 is
mutated, PTCH2 mRNA is up-regulated.89
NFkB
A good example of the importance of embryonic growth reg-
ulatory pathways in BCC carcinogenesis is the discovery that
defects in one of the components of the NFkB signalling path-
way can also cause BCC (own data, unpublished). The CYLD
gene, which is mutated in familial cylindromatosis or Brooke–
Spiegler syndrome, is a de-ubiquitinating enzyme that negat-
ively regulates NFkB.91–93 Its target is TNFR-associated factor
2 (TRAF2) and, to a lesser extent, TRAF6. Both TRAF2 and
TRAF6 are implicated in the transduction of EDA ⁄EDAR ⁄
EDARADD signals94–97 and thus in the development of skin
appendages, as mutations in EDA, EDAR, EDARADD and
TRAF6 can all cause ectodermal dysplasias in humans and
mice.96,98–100 Recent data indicate that EDA can repress
b-catenin-dependent transcription,101 suggesting a regulatory
connection between the EDA and PCTH pathways and hinting,
again, at the central importance of the PTCH route for basal
cell carcinogenesis. b-Catenin can control EDAR expression,
showing that the EDA–NFkB pathway is subject to negative
autofeedback.
Normally, activation of NFkB is caused by phosphorylation
of the NFkB inhibitor IkB through the IkB kinase complex.102
The gene mutated in incontinentia pigmenti, NEMO (NFkB
essential modulator), is part of the IkB kinase complex. Phos-
phorylation of IkB leads to its ubiquitination and subsequent
disposal through the proteasome. CYLD was found to interact
with NEMO.91–93 This possibly transient interaction is
required for its function, the de-ubiquitination of TRAF2 and
TRAF6. The latter proteins are auto-ubiquitinating and need
the ubiquitin tag for their normal function. Hence, CYLD
down-regulates NFkB activation. Interestingly, CYLD mutations
were recently found in familial trichoepithelioma. The latter
tumour is also observed in familial cylindromatosis and resem-
bles BCC to such a degree that a distinction is often difficult
to make.103 Indeed, we have recently observed the occurrence
of a BCC in a patient suffering from familial cylindromatosis.
These observations suggest that the NFkB pathway, which is
involved in inflammation and in the embryogenesis of epithe-
lial appendages, can also play a role in BCC. It should be of
interest to examine sporadic BCCs for mutations in one of the
components of the NFkB pathway. Likewise, patients suffering
from multiple BCCs may harbour CYLD mutations.
Unknowns
Finally, Rombo and Bazex syndromes are known to predispose
to BCC. Both are characterized by the presence of numerous
small cysts on the face and chest, as well as by hypotrichosis.
The cysts contain vellus hairs.104,105 Rombo syndrome is
distinguished by striking degeneration of elastic fibrils in
sunlight-exposed areas causing dramatic skin alterations
called atrophoderma vermiculatum.104,105 In Bazex syndrome,
so-called ice-pick scars are seen on the backs of the hands.
This disorder is X-linked and has been mapped to Xq24–
27.106 Rombo syndrome is probably autosomal dominant, but
otherwise very similar to Bazex. Identification of the causative
genes should contribute significantly to our knowledge of hair
follicle and BCC biology.
Acquired genetic changes in basal cell carcinoma
p53
The most common genetic aberrations in human skin cancers
are found at the level of the p53 gene.107 The p53 gene
encodes a phosphoprotein that is involved in cell-cycle control
and the maintenance of chromosomal stability.108,109 In
response to cellular stress, for example DNA damage, p53 is
activated through phosphorylation.110,111 MDM2 can associate
with p53 and regulates its level and activity depending on the
phosphorylation status of p53. When dephosphorylated, p53
will bind to MDM2 and is then degraded through the ubiqu-
itin–proteosome pathway.112,113 In response to DNA damage,
p53 is phosporylated by DNA damage-sensing proteins such
as ATM and becomes detached from MDM2, resulting in
stabilization and activation of target genes regulated by p53
(Fig. 2).114 The response to DNA damage is either growth
arrest, senescence or apoptosis.115 The relative cellular content
of p53 determines the response following DNA damage; when
the content is low to moderate, cells will go into cell-cycle
arrest to allow DNA repair, but when p53 levels are high, cells
will progress to apoptosis.116 p53 is capable of stimulating
proapoptotic Bax expression117,118 (see also below). In normal
skin, wild type p53 is not detectable but appears within 2 h
after UV irradiation, with peak levels at 24 h after irradiation
and again undetectable levels at 36 h after irradiation.119
Mutant p53 can accumulate in cells and p53 mutations have
been detected in about half of all BCCs.120,121 Furthermore, it
was found that histologically proven aggressive BCCs are signi-
ficantly associated with increased p53 expression, probably
representing the mutated form although that assertion could
not be established with certainty. However, it is striking that
patients suffering from Li–Fraumeni syndrome do not show
increased incidence of BCC. Consequently, it seems reasonable
to assume that p53 mutations are secondary events in BCCs,
occurring after tumour initiation. Considering the apparently
limited contribution of DNA damage and chromosome insta-
bility to the BCC phenotype, the relevance of p53 mutations
for BCC growth remains to be demonstrated. After all, in the
absence of genetic damage, p53 activation will not occur.
Moreover, one of the hallmarks of p53 dysfunction, aberrant
mitosis, perhaps as a consequence of centrosome amplifica-
tion,122 has never been observed in BCC.123
In BCC patients, in a study comparing sunscreen users and
non-users, it was shown that sunscreen users showed a signi-
ficantly lower level of p53 mutations in their BCCs than
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non-users,124 again suggesting that p53 mutations in BCCs
are secondary events that may not contribute significantly to
tumorigenesis. Mutational hotspots have been identified, with
two-thirds of the mutations occurring at nine different
sites.125 Inactivation of p53 occurs predominantly by point
mutation of one allele followed by loss of the remaining
wild-type allele.126 The p53 gene shows UV signature muta-
tions, i.e. predominantly C(C) ﬁ T(T) conversions.125,127 In
33% of BCCs found in Korean patients p53 mutations were
detected69 and up to 50% of the BCCs in Caucasian patients
showed this mutation,120,121 thus suggesting that different
ethnic factors play a role in BCC carcinogenesis although dif-
ferences in sun exposure (with the Westerners engaging
more in recreational sunning) may just as well account for the
differences observed.
p63
The p63 gene, a p53 homologue, encodes multiple products
and is restricted to cells with high proliferation potential and
absent from cells undergoing terminal differentiation.128 p63
has a nucleoplasmic distribution pattern in the basal compart-
ment of stratified epithelia such as skin, tonsil, bladder and
certain subpopulations of basal cells in prostate, breast, uterine
cervix and bronchi.129–131 p63-deficient mice have striking
developmental defects such as absence or truncation of limbs,
absence of hair follicles, teeth and mammary glands, and the
skin lacks stratification and differentiation.132 This indicates that
p63 is essential for several aspects of differentiation during
embryogenesis. Several isoforms of p63 can bind to p53 con-
sensus sequences and activate p53 target genes. Isoform TAp63c
is capable of inducing cell-cycle arrest and apoptosis.133 The DN
isoforms, lacking the N-terminus, are unable to induce tran-
scription, and have an antiapoptotic effect by rendering p53
and TA isoforms inactive. p63 is only rarely mutated in BCC.134
It was shown that p63 functions not only as a stem-cell mar-
ker of keratinocytes135 but may also maintain the stem-cell
phenotype.136 In keeping with its basal localization in normal
epidermis, BCC cells express p63.131,137 It was shown that aber-
rant expression of p63 altered the UVB-induced apoptotic path-
way suggesting that down-regulation of this protein in response
to UV irradiation is important in epidermal apoptosis.138
Immunological factors
Immunosuppression
Organ transplant recipients are at greater risk for developing
malignancies because of the prolonged, often life-long, immu-
nosuppressive therapy.139–141 SCC of the skin is the most
common malignancy occurring in the setting of solid-organ
transplantation and immunosuppression, and its incidence
increases substantially with extended survival after transplanta-
tion.142 SCC occurs more frequently in transplant patients,143
whereas in the general population BCC is three to six times
more frequent than SCC.144 It was shown in Australian heart
transplant recipients that the number of skin cancers is signifi-
cantly correlated with both age at transplantation and duration
of follow-up.145 In Europe, 40% of renal transplant recipients
develop skin cancer within 20 years after grafting.146 Heart
transplant recipients are at higher risk than kidney transplant
recipients most probably due to the fact that they receive
higher doses of immunosuppression agents,147 but it cannot
be overlooked that the different types of immunosuppressive
agents have different effects in this respect. Increased inci-
dence of BCC has not been described in organ recipients.
From the available data, it seems clear that immunosuppres-
sion as practised after organ transplantation does not increase
the risk of developing BCC. As stated above, the incidence of
BCC seems not to be affected by PUVA treatment. A dimin-
ished response to skin application of dinitrochlorobenzene
was found in people with SCC but not in patients with BCC,
again supporting the notion that the incidence of BCC is not
affected by immune status.148
Fig 2. p53 signalling. DNA damage induces stabilization of p53. In the case of repairable damage (A), p53 triggers p21. This in turn inhibits
cyclin-dependent kinases. As a consequence, Rb remains unphosphorylated and stalls the cell in the G1 phase of the cell cycle. In the case of
irreparable DNA damage (B), p53 also induces Bax which then competes with Bcl2 in the mitochondrial membrane. As a result, cytochrome C is
released from the mitochondria, triggering the caspase cascade that causes apoptosis.
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Human immunodeﬁciency virus
Seemingly in contradiction to the lack of an increase in the
incidence of BCC in organ recipients, people suffering from
acquired immune deficiency syndrome (AIDS) have shown an
elevated risk for the development of BCC.149,150 Human
immunodeficiency virus (HIV) patients with BCC more fre-
quently show blue eyes, blond hair, family history and exten-
sive prior sun exposure.151 The pigmentation phenotype is
probably an independent risk factor that is added to the
increased risk of BCC conferred by the immunosuppression.
There have been some reports of BCCs metastasizing in people
suffering from AIDS,152,153 suggesting that immune surveil-
lance is one of the factors determining the normally non-
metastatic nature of the BCC. Why immunosuppression by
HIV increases the risk of BCC, whereas pharmaceutical immu-
nosuppression does not is not clear. The depletion of CD4
lymphocytes by HIV may lead to a more pervasive defect in
adaptive antitumour immunity than does mere functional sup-
pression by commonly used immunosuppressive compounds.
Human leucocyte antigen (HLA) haplotypes
The major histocompatibility complex (MHC) genes code
for membrane proteins that play important roles in control-
ling immune responses.154 There are two classes of genes,
class I (HLA-A, -B, -C) and class II (HLA-DR, -DQ, -DP),
which play a role in host defence against the development
and spread of tumours.155 For example, loss of class I anti-
gens is related to tumour progression in melanomas.156 Fur-
thermore, abnormalities in cell-mediated immunity have
been reported in patients with multiple BCCs.157 Whereas
normal skin shows high levels of class I molecules, BCC
shows either complete absence or heterogeneous expres-
sion.158 All class I-negative tumours were histologically pro-
ven to be aggressive, whereas all non-aggressive BCCs were
class I-positive. The low levels or absence of expression of
class I antigens may result in escape from recognition by
cytotoxic T cells, which then facilitates tumour growth.159
Evidence for the involvement of HLA genes in the develop-
ment of skin cancer was provided by Bouwes Bavinck
et al.160 These authors showed that the presence of HLA-
DR7 and a decrease of HLA-DR4 are significantly associated
with BCC. This corroborates the previous finding of Rompel
et al. 161 that HLA-DR4 is decreased in BCC, especially in
patients with multiple BCCs located on the trunk.162 The
authors suggested a protective role for HLA-DR4 against the
development of BCC. HLA-DR1 is weakly associated with
the development of multiple BCCs at an early age.163 Fur-
thermore, Bouwes Bavinck et al. presented two studies
showing a correlation between HLA-A11 expression and
skin cancer in immunosuppressed renal transplant recipi-
ents.164,165 One of these studies showed that HLA-A11 was
associated with resistance to skin cancer in renal transplant
recipients,164 while another study, in Australia, showed that
renal transplant recipients with HLA-A11 had an increased
risk for developing skin cancer.165 This apparent discrepancy
may be the result of different genetic backgrounds and
differential environmental factors.
Human papillomavirus
Although HPV has been associated strongly with malignant
progression of warts to SCC and with epidermodysplasia
verruciformis,166 different oncogenic subtypes of the virus
were found in 60% of BCCs from immunosuppressed patients
in contrast to 36% of BCCs from non-immunosuppressed
patients, suggesting that these viruses may be involved in the
development of BCC.167 In renal transplant recipients with
skin cancer HPV 5 ⁄8 DNA could be detected,28 and Weinstock
et al.30 suggested immunosuppression to be a factor in BCC
carcinogenesis by affecting HPV infection.
Tumour stem cells
Several cell types have been suggested to be the precursor
cells or stem cells for BCC: interfollicular basal keratinocytes,
basal keratinocytes from hair follicles or sebaceous gland
cells.168–173 In general, stem cells have a relatively undifferen-
tiated and slow-cycling phenotype, but can be stimulated to
proliferate and give rise to transient amplifying cells which
have a limited proliferative potential.174 Stem cells may be the
target of carcinogens and as such play an important role in
tumorigenesis. One observation suggesting that uncommitted
stem cells are the most likely cells of origin for human skin
cancer is the fact that sunlight exposure in childhood may
contribute to tumours many decades later.175 As first sugges-
ted by Taylor et al. 176 the ultimate source of stem cells in the
skin is the bulge region of the ORS.177–179 As a result, hair
follicles are likely to play an important role in skin homeo-
stasis, wound healing and tumourigenesis.174 Chemically
induced BCCs in rats arise from hair follicles,180 but it is not
known whether this is also the case in humans.
Histologically, BCCs may resemble hair follicles,11 and may
show characteristics from both bulge region stem cells and
transient amplifying cells.181 In particular, BCC can histologi-
cally resemble trichoepithelioma, a benign hair follicle
tumour.182 The suprabulbar region of the ORS of the hair
follicle has an immunohistochemical profile that is almost
indistinguishable from that of a BCC.169,183,184 The hair fol-
licle hypothesis is further supported by the fact that when a
carcinogen is added in the anagen phase, in which the hair
follicle bulge region cells undergo transient amplification,
BCCs are generated more frequently.185 Furthermore, BCCs
seldomly occur on non-hairy skin.181 Support for the hair fol-
licle hypothesis can be found in the expression of the basal
cell adhesion molecule (B-CAM) in normal and diseased
skin.186 The fact that this cell-surface protein is preferentially
expressed in suprabasal cell layers and the ORS of the hair
follicle, and also shows high levels of expression in BCCs,
suggests that BCCs originate from hair follicles rather than
from basal keratinocytes, which are negative for B-CAM in
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normal skin. However, the lack of cytokeratin 15 expression
in the tumour cells suggests that BCCs do not differentiate
towards a hair bulge cell fate.187
Howell and Mehregan188 reported that the tiny pits in the
epidermis of palms and soles characteristic of Gorlin syn-
drome64 (or NBCCS, see above) occasionally show basaloid
budding into the dermis, and have therefore suggested that
they resemble tiny BCCs. This observation was taken to sup-
port the idea that BCCs can originate from interfollicular
epidermis. There is no further proof to support this notion.
Finally, our current understanding of the molecular genetics of
BCC as outlined above also supports the notion that the hair
follicle stem cell is the progenitor cell of the BCC. In all, it
seems as if the BCC cell is a hair follicle stem cell in which the
normal differentiation and anagen-initiation programme, of
which the SHH network forms the backbone, has gone awry.
Carcinogenesis
Tumour formation results from a disruption of the normal
balance between cell proliferation and cell death.189 Three
large categories of genes affect cellular proliferation and survi-
val, i.e. growth-promoting oncogenes, tumour suppressor
genes and mutator or caretaker genes.190 The normal counter-
parts of oncogenes, i.e. the proto-oncogenes, are crucial in
regulating normal cell cycling and division, differentiation and
apoptosis.191–193 When these become mutated or amplified
they can overcome the normal restraints of cell growth.194,195
So-called ‘tumour suppressor’ genes can be involved in differ-
entiation pathways that are coupled to cell growth, PTCH
being a good example in point, and mutations or deletions of
such genes have been reported in various types of cancer.196–198
However, mismatch repair genes are also classified as tumour
suppressors and the functional distinction between oncogenes,
proto-oncogenes and so-called tumour suppressors is blurring.
A more useful distinction is that in general (proto-)oncogenes
need to be activated, and tumour ‘suppressor’ genes inacti-
vated for malignant transformation to occur.199 Defects in
the latter appear to be more common than defects in onco-
genes.200 ‘Mutator’ or caretaker genes (involved in DNA
repair) maintain the genome integrity and when their func-
tion is altered, mutations can accumulate more frequently.190
Proliferation vs. differentiation in basal cell carcinoma
Proliferation indices vary greatly for the different subtypes of
BCC, but in general relatively high percentages of proliferating
tumour cells are found.201–204 Based on immunohistochemical
detection of the proliferation marker Ki-67, an average of
20% of the cells in BCC are found to be prolifer-
ating.202,203,205,206 The proliferating cell nuclear antigen
(PCNA) is present in <10% of non-recurrent BCCs, while
recurrent BCCs show PCNA expression in >30% of the
tumour cells.207,208 In nodular and superficial BCC the prolif-
erative activity is mainly restricted to the periphery of the
tumour nests, whereas morphea-like tumours show a more
scattered pattern of proliferating cells.202,206 An explanation
for the zonal distribution of proliferation-potent cells may be
that tumour cells migrating towards the centre of the tumour
nests become more differentiated, or have less access to nutri-
ents, resulting in lower proliferation potential.209 Alternat-
ively, adhesive properties may determine both behaviours.
Markers for the arrest of cell proliferation include the
A-type lamins, also sometimes known as statins.210 Nuclear
lamins are intermediate filament proteins that form a network
at the nucleoplasmic site of the nuclear membrane and can be
divided in two subtypes, i.e. A-type lamins (lamin A, lamin
AD10 and lamin C) and B-type lamins (lamin B1 and lamin
B2).211,212 Aberrant expression patterns of lamins have been
described in cancer and it is thought that the nuclear matrix
plays a role in carcinogenesis.213 In general, A-type lamin
expression is correlated with a non-proliferating, differentiated
state of cells and tissues,214 and therefore altered expression of
A-type lamins can be expected in cancer. In BCC, it was
recently reported by Venables et al. 215 that the absence of
lamin A correlated with rapid growth, while the absence of
lamin C correlated with slow growth. Furthermore, it was
reported that the expression of A- and B-type lamins varies
with differentiation in normal epidermis216 and skin
tumours.216,217 These authors support the idea that expression
of A-type lamins, but not B-type lamins is associated with
the differentiation phenotype of the tumours. Recently, Tilli
et al. 218 reported four stages in BCC development based on
different patterns of A-type lamin expression. Stage 1 compri-
ses lamin A-negative, Ki-67-positive BCCs, representing the
origin of BCC, while stage 2 comprises lamin A-positive,
Ki-67-positive BCCs. As tumour growth slows down, lamin C
is first relocated to the nucleolus in stage 3 and in stage 4
lamin C expression is largely diminished.
The fact that BCC shows relatively high percentages of pro-
liferating tumour cells is not in line with the clinical finding
that BCC is usually a slow-growing tumour.219 Therefore, cell
loss must be considered as an important factor in the net
growth of BCC. Already in 1972, Kerr et al.220 reported that a
high apoptotic rate in BCC might account for the seemingly
paradoxically slow growth rate. Furthermore, Mooney et al.221
showed that BCCs do indeed exhibit a high apoptotic rate as
based on in situ end-labelling of nicked DNA ends [using
TUNEL staining, terminal deoxynucleotidyl transferase (TdT)-
mediated deoxyuridine triphosphate (dUTP) nick-end label-
ling].
Apoptosis in epidermis and basal cell carcinoma
Apoptosis, a form of programmed cell death, is characterized
by cell shrinkage and fragmentation.222 Apoptosis is one pro-
cess among others that is necessary for the correct develop-
ment of an embryo,223 and to eliminate autoreactive
lymphocytes.224 Abnormal, unwanted or damaged cells are
removed by apoptosis without the involvement of the
immune system, but through rapid phagocytosis of apoptotic
cells before lysis, which prevents inflammation.225 In this
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respect the process of programmed cell death can be clearly
distinguished form accidental cell death, i.e. necrosis.
During the different phases of apoptosis various sets of mol-
ecules act in an orchestrated fashion. These include:
1 Death ligands and death receptors. The family of death
receptors is characterized by two to five copies of cysteine-rich
extracellular repeats and a death domain within the intracel-
lular carboxy-terminus of the receptor (the death domain).226
When these death receptors are bound by ligands, apoptosis
can be induced. Fas is an example of a type I transmembrane
receptor which mediates apoptosis upon binding of the oligo-
merizing Fas ligand (FasL).227 Fas is expressed on several
different cell types, while expression of FasL is restricted to
immune cells, including T and B lymphocytes, macrophages
and natural killer cells.228,229 Ligation of FasL to Fas causes
rapid death-inducing signalling complex formation, which
recruits and activates pro-caspase-8, thus triggering the apop-
totic caspase cascade (see below).
2 Bcl-2 protein family. Many studies concentrate on the
Bcl-2 family of apoptosis-regulating proteins.230,231 Bcl-2 was
first discovered in B-cell lymphomas showing a t(14:18)
translocation,232 resulting in a Bcl-2-immunoglobulin-heavy
chain fusion gene.233 This leads to overexpression of the
antiapoptotic Bcl-2 protein. The protein has been shown to
suppress apoptosis induced by various stimuli, such as deple-
tion of interleukin (IL)-3 and IL-4234,235 p53-induced apop-
tosis,236 glucocorticoid treatment,237 and c-myc induced
apoptosis.238 Bcl-2 expression has been localized to long-lived
(stem) cells in self-renewing human tissues.191 The protein
is associated with the membranes of mitochondria, endo-
plasmatic reticulum and nucleus,239 and bears seven
phosphorylation sites of which ser70 is critical for the apop-
tosis-suppressing function of Bcl-2.240 A large number of
Bcl-2-related proteins230,231,241,242 have been isolated, which
can act either as apoptosis-inducing (e.g. Bax, Bcl-xs) or
apoptosis-suppressing agents (Bcl-xl). Heterodimerization
between these family members determines whether a cell will
die or not.243,244
3 Caspases. The aspartate-specific cysteine protease (caspase)
cascade appears to be the main pathway for clearance of cellu-
lar constituents during the execution phase of apoptosis.245
Several human caspases have been identified that share similar-
ities in amino acid sequence, structure and substrate specif-
icity.246,247 Caspases show a high specificity for the conserved
QACXG sequence, resulting in the cleavage after aspartic acid
(Asp) residues.248 The caspase family comprises apoptotic ini-
tiators (e.g. caspase-2, -8, -9 and -10) and apoptotic execu-
tioners (e.g. caspase-3, -6 and -7).246 Caspase-3 seems to be
responsible for the majority of apoptotic effects, and is sup-
ported by caspase-6 and -7. These three executioner caspases
are important in the cleavage and degradation of several sub-
strates, target proteins that are involved in RNA splicing, DNA
repair, and scaffolding of the cytosol and the nucleus. Upon
induction of apoptosis, caspase-3 cleaves the inhibitor of the
caspase-activated DNAse, resulting in degradation of DNA into
oligonucleosomal fragments.249,250 Lamin A is cleaved by
caspase-6251,252 while in addition, cytoskeletal filaments such
as cytokeratins are cleaved by caspase-6.253 The externalization
of phosphatidyl-serine at the cell membrane during apoptosis
is also caspase-dependent.254 The nuclear matrix protein
poly(ADP-ribose) polymerase is also proteolysed by caspases
during apoptosis.255
Inhibitors of apoptosis proteins, which are constitutively
present in cells,256,257 for example, bind to and inhibit
caspase-3 and -7 as well as pro-caspase-9, but not capase-1,
-6, -8 or -10.
When apoptosis occurs inappropriately it may cause degen-
eration of normal tissue architecture or function. On the other
hand, when apoptosis fails to occur this can give rise to
dysregulation of tissue homeostasis, as a result of which
neoplasms can arise.
Apoptosis in the epidermis is a common phenomenon. In
the morphogenesis of human fetal skin and maintenance of
adult epidermis apoptosis plays a pivotal role.258 For example,
the apoptosis machinery is activated during the normal ter-
minal differentiation process in keratinocytes.259 In fetal skin,
cells undergoing apoptosis are present in several epidermal cell
layers, whereas in neonatal epidermis these are found in the
terminally differentiating granular cell layer, and in adult skin
the spinous cells also show occasional apoptosis.258 Further-
more, apoptosis occurs upon excessive UV light exposure,
resulting in irreparable DNA damage (see also Fig. 2).260 A
significant negative correlation between the expression of
either p53 or bcl-2 with the development of BCC has been
described previously.261 Mutation of p53 or overexpression of
bcl-2 is sufficient to enhance the formation of BCC by suppres-
sing apoptosis.262,263
Altered expression of Bcl-2 family member proteins in non-
melanoma skin cancer has been reported extensively before,264
suggesting that dysregulation of expression of these proteins
may be a possible explanation of the indolent growth beha-
viour of BCC.206,265 Bcl-2 is in general homogeneously
expressed in BCC,206,266–268 while the apoptosis-inducing Bax
protein is also expressed at high levels.206,264 These data
clearly show that a considerable proportion of cells in BCC are
in principle capable of undergoing apoptosis, corroborating
the earlier findings of Mooney et al. 221
Another apoptosis-inhibitor protein called survivin is
expressed in 81% of BCCs, whereas it is not detected in nor-
mal skin, suggesting a contribution to the progression of
BCC.269
Also, Fas-mediated apoptosis may be important for skin
homeostasis. Hill et al.270 suggested that dysregulation of
Fas–FasL interactions may be central to the development of
skin cancer. In normal skin, Fas is expressed in cytoplasmic
membranes of the basal cell layer, while after sun exposure
the expression of Fas is up-regulated in the entire epidermis.
After further UV exposure, Fas expression is again down-regu-
lated, resulting in negative staining in BCC.271 BCCs express
FasL, however, strongly and diffusely, providing evidence for
an escape from local immunesurveillance by the induction of
apoptosis in the peripheral T lymphocytes.272
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Current and future therapeutic
modalities – from surgical to biological
Various surgical and non-surgical therapies are available for
the treatment of BCC.273 Medical history of the patient,
age, tumour localization and size, physical condition, histo-
logical outcomes and cosmetic aspects will eventually deter-
mine the choice of therapy. Furthermore, Telfer et al.274
published guidelines for the management of BCC, presenting
evidence-based guidance for treatment. In spite of the fact
that surgical excision is still the most prominent therapy
used, non-invasive therapies such as photodynamic therapy
(PDT)275 or topical application of 5-fluorouracil (5-FU)276
are currently becoming more and more interesting in select-
ive cases, especially because of the improved cosmetic
outcome.
Surgery
Throughout this review we have used the term ‘basal cell car-
cinoma’ instead of ‘basalioma’, in keeping with current prac-
tice in the Netherlands. ‘Carcinoma’ suggests malignancy as
well as full metastatic potential. Dermatological surgeons treat
BCC as such and justify mutilating procedures by referring to
the presumed malignant nature of the lesion, dreading recur-
rence as if it were melanoma. While definitely capable of
causing local tissue destruction if left untreated, BCCs rarely, if
ever, metastasize. Hence one may wonder whether it is really
necessary to eradicate every last trace of tumour surgically. A
recurrence often can be quite easily treated and will follow
only about 1Æ6–5% of conventional excisions aimed at free
margins (a procedure that can leave undetected residual cells,
particularly in the morpheaform growth type).277,278 As dis-
cussed below, biological therapies offer great promise and
may be used as adjuvants to conventional excision, allowing
for more conservative surgery in the future.
Induction of apoptosis
Many currently used antineoplastic agents exert their therapeu-
tic effects through the induction of apoptosis. Different cell
types vary profoundly in their susceptibility, suggesting the
existence of distinct cellular thresholds for apoptosis induc-
tion.279 For example, BCC cells overexpressing IL-6 are resist-
ant to UV irradiation and PDT-induced apoptosis.280
Furthermore, it was shown that de novo p53 synthesis or stabil-
ization of p53 is essential to induce apoptosis in BCC.281
Overexpression of the antiapoptotic Bcl-2 has also been linked
to resistance of cancers to various chemotherapeutic drugs.282
In BCC, interferon (IFN)-a induces apoptosis and is thus
effective in the treatment.283 Untreated BCC cells express FasL
but not the receptor, but in IFN-a-treated BCC patients the
tumour cells express both FasL and receptor, whereas the
peritumoral infiltrate mainly consists of Fas-receptor-positive
cells.284 Therefore, with IFN-a treatment, BCC most likely
regresses through apoptosis.
Topical treatment of BCC with 5-FU has also been pro-
ven to be very successful. Up to 90% of treated BCCs show
regression when 5-FU is applied in a phosphatidyl choline-
based cream285 or when it is locally injected in an epineph-
rine-containing gel.276 The regression of tumours treated
with 5-FU is probably caused by enhancing apoptosis in
the tumour cells.286 Recently, Nakaseko et al. 287 reported
that apoptosis is involved in regression of the lesion after
PDT in actinic keratosis. This therapy is also used for treat-
ment of BCC,288 where tumour cells may also undergo
apoptosis.
Phytochemicals known to induce apoptosis are also being
applied in cancer prevention and therapy.289 Recently, Levin
and Maibach290 published an overview of plant-derived
drugs and treatments in dermatology. It was shown that
application of green tea polyphenolic fractions reduced UV-
induced erythema, gave rise to a decrease in sunburns and
could also reduce the number of UV-induced mutations in
DNA.291 Oral and topical application of black tea extracts
also decreased photochemical damage to the skin.292 Fur-
thermore, in mice bearing skin tumours, tumour growth
was inhibited by 70% after treatment with black tea, which
was established by inhibition of proliferation and enhanced
apoptosis.293 Ajoene, an organosulphur compound of gar-
lic,294 has been shown to induce apoptosis in human
promyeloleukaemic cells.295 Recently, it was shown that
ajoene can induce apoptosis in the human keratinocyte cell
line HaCat and has a diminishing effect on BCC in vivo by
down-regulating the expression of the apoptosis-suppressing
protein Bcl-2.296 Apart from the induction of apoptosis by
directly targeting its mediators, the obvious role of the SHH
pathway in BCC growth suggests that interference with this
pathway may also be used to treat BCC. Indeed, it was
recently shown that a SHH antagonist, the Veratrum alkaloid
cyclopamine (11-deoxojervine) can be used to treat BCC.297
Cyclopamine binds directly to Smoothened, which explains
its activity in tumours characterized by activated SHH path-
ways.298 Interestingly, its application to the surface of the
tumour resulted not only in the rapid induction of apopto-
sis but also influenced the differentiation status in seven of
seven tumours.299
Modulation of differentiation
Retinoids (vitamin A metabolites and analogues) have also
been shown to have suppressive effects on tumour promotion
when administered in high doses, and the mechanism appears
to be associated with modulation of growth, differentiation
and apoptosis.300 However, clinical experience suggests that
the antitumour activity of retinoids when administered in tol-
erable doses is limited as a result of adaptation of the
tumour’s retinoid metabolism.301 Retinoic acid metabolism
blocking agents (RAMBAs) such as liarozole, possibly com-
bined with retinoids in a relatively low dose, may offer a
more tolerable and effective means of slowing tumour pro-
gression.301,302
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Immunomodulation
Because BCCs often elicit a strong inflammatory response,
recent studies have sought to evaluate the effect of immuno-
modulatory compounds. One of the most promising is imiq-
uimod, a Toll-like receptor 7 ⁄8 agonist that enhances the
endogenous cytokine response (among others, INF-a, IL-10),
stimulating the T-helper 1-mediated inflammatory responses.
Several recent studies suggest that imiquimod can be used as a
monotherapy, with excellent complete response rates (80%
and more).303–306 The tumours are infiltrated by macrophages
and show an extensive apoptotic response.
Conclusion
In order to develop better pharmacological treatments for BCC,
we need to understand its biological nature. As long as it is con-
sidered a malignancy, radical surgery seems to be justified, in
particular for tumours with a morpheaform growth pattern.
Hence the crucial question is whether BCC is truly cancer. If we
are defining cancer as a clonal expansion of cells that are no lon-
ger under host control, and are not subject to replicative senes-
cence and apoptosis, BCC is true cancer. On the other hand, the
lack of defects in the control of genomic integrity and the appar-
ent inability to metastasize seem to suggest that there are funda-
mental differences between BCC and other malignancies. For
example, there seems to be an important difference between
frank malignancies and BCC with regard to the timing of the
activation of the SHH pathway in the process of tumorigenesis.
In many tumour types, such as those of the lung or the pancre-
atic duct, the SHH route has to be reactivated since it is not nor-
mally active in those tissues during adult life but only during
embryogenesis. In the normal adult hair follicle on the other
hand, the SHH pathway is subject to cyclic activation.307 Hence,
aberrations in this constitutional activity of the SHH pathway in
the hair follicle may be initiating events in BCC tumorigen-
esis.308 In other tumours, on the other hand, SHH activation
seems to contribute to tumour progression rather than to initi-
ation. In view of the foregoing, it is our opinion that the desig-
nation ‘basalioma’ is most appropriate, because it emphasizes
the proliferative nature of the disorder, and at the same time
indicates the limited malignant potential.
The availability of proapoptotic and immunomodulatory
compounds for the treatment of BCC may change therapy in the
near future. For the majority of patients, surgery may no longer
be the first treatment option. Tumours that are currently resect-
ed with a wide margin, a procedure that can result in mutilating
defects, might be treated by limited primary excision followed
by adjuvant therapy using an immunomodulator, a proapoptotic
agent and ⁄or a cell-signalling modulator.
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